Mirdametinib (MEK Inhibitor)

DRUG2 trials

Sponsors

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Conditions

HealthyHepatic ImpairmentHistiocytic NeoplasmNeurofibromatosis Type 1-Associated Plexiform NeurofibromasOther MAP-K Pathway Driven Diseases

Phase 1

Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

RecruitingNCT06997276

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyHealthy, Hepatic Impairment

Start: 2025-05-07End: 2026-10-31Target: 32Updated: 2026-08-24

Unknown Phase

Individual Patient Compassionate Use of Mirdametinib

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyHistiocytic Neoplasm, Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, Other MAP-K Pathway Driven Diseases

Updated: 2026-05-08